Cristina Mecucci Selected Research

Nucleophosmin

5/2008	Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
3/2008	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
3/2008	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
7/2007	Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants.
4/2007	Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
2/2007	Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
12/2006	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
9/2006	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
7/2006	Nucleophosmin and cancer.
6/2006	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cristina Mecucci Research Topics

Disease

25	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2021 - 05/2002
20	Neoplasms (Cancer) 02/2022 - 08/2002
16	Leukemia 01/2022 - 05/2005
14	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2021 - 08/2002
9	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 06/2022 - 01/2006
8	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2020 - 02/2002
6	Lymphoma (Lymphomas) 01/2022 - 12/2002
5	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 08/2002
4	Residual Neoplasm 01/2020 - 08/2005
3	Eosinophilia 02/2022 - 06/2021
3	Hypereosinophilic Syndrome (Loeffler Endocarditis) 05/2005 - 04/2004
3	Infections 12/2003 - 03/2002
2	Chromosome Aberrations (Chromosome Abnormalities) 02/2022 - 05/2006
2	Trisomy (Trisomies) 10/2019 - 03/2002
2	Genetic Translocation (Chromosomal Translocation) 01/2016 - 08/2005
1	GATA2 Deficiency 01/2022
1	Primary Myelofibrosis (Myelosclerosis) 09/2021
1	Thyroiditis 12/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2020
1	Hemoglobinopathies 01/2020
1	Monosomy 10/2019
1	Iron Overload 11/2017
1	Thalassemia 11/2016
1	Sickle Cell Anemia (Hemoglobin S Disease) 11/2016
1	Lymphoid Leukemia 07/2015
1	Autoimmune Diseases (Autoimmune Disease) 05/2015
1	Gliosarcoma 03/2015
1	Malignant Mesothelioma 03/2015
1	Sarcoma (Soft Tissue Sarcoma) 03/2015
1	Carcinogenesis 02/2014
1	Aneuploidy (Aneuploid) 02/2014
1	Chromosomal Instability (Chromosome Stability) 02/2014
1	Blast Crisis (Blast Phase) 01/2014
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2014
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 10/2009
1	Acute Promyelocytic Leukemia 01/2009
1	Acute Myelomonocytic Leukemia 10/2007
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 04/2007

Drug/Important Bio-Agent (IBA)

15	NucleophosminIBA 05/2008 - 01/2005
12	nuclear pore complex protein 98IBA 01/2022 - 05/2002
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2005
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
6	Biological ProductsIBA 07/2021 - 09/2003
3	RNA (Ribonucleic Acid)IBA 10/2020 - 01/2016
3	Phosphotransferases (Kinase)IBA 01/2020 - 08/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2014
3	AntibodiesIBA 01/2019 - 11/2006
3	Imatinib Mesylate (Gleevec)FDA Link 10/2009 - 04/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 02/2022 - 06/2021
2	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 02/2022 - 10/2009
2	Oncogene Proteins (Oncogene Protein)IBA 01/2022 - 02/2014
2	NucleotidesIBA 01/2020 - 03/2008
2	Dacarbazine (DIC)FDA LinkGeneric 10/2019 - 02/2002
2	Protein Isoforms (Isoforms)IBA 03/2013 - 03/2006
2	Genetic Markers (Genetic Marker)IBA 08/2005 - 05/2005
2	Tyrosine (L-Tyrosine)FDA Link 05/2005 - 08/2002
1	Glycogen Synthase (Synthase I)IBA 06/2022
1	Small Interfering RNA (siRNA)IBA 06/2022
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 02/2022
1	N-acetylpenicillamineIBA 01/2022
1	Atorvastatin (Lipitor)FDA Link 01/2022
1	Cytokine Receptors (Cytokine Receptor)IBA 06/2021
1	Immunoglobulin A (IgA)IBA 12/2020
1	CytokinesIBA 01/2020
1	GlucocorticoidsIBA 01/2020
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2020
1	Calcium-Transporting ATPases (Ca2+ ATPase)IBA 01/2020
1	Interleukin-7 (Interleukin 7)IBA 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019
1	venetoclaxIBA 01/2019
1	Bortezomib (Velcade)FDA Link 01/2019
1	Lenalidomide (CC 5013)FDA Link 07/2018
1	Pharmaceutical PreparationsIBA 07/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2017
1	IronIBA 11/2017
1	Hemoglobins (Hemoglobin)IBA 11/2016
1	Untranslated RNA (Noncoding RNA)IBA 01/2016
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2016
1	MTOR InhibitorsIBA 01/2016
1	Long Noncoding RNAIBA 01/2016
1	Janus Kinase InhibitorsIBA 10/2015
1	AsbestosIBA 03/2015
1	trioctyl phosphine oxide (TOPO)IBA 03/2014
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 03/2014
1	Epirubicin (Ellence)FDA LinkGeneric 03/2014
1	Cyclin D1IBA 02/2014
1	Nuclear Pore Complex Proteins (Nucleoporins)IBA 02/2014
1	Nuclear Proteins (Protein, Nuclear)IBA 05/2008
1	MicroRNAs (MicroRNA)IBA 03/2008
1	Topoisomerase II InhibitorsIBA 10/2007
1	Nuclear Export Signals (Nuclear Export Signal)IBA 07/2007
1	OligonucleotidesIBA 05/2007
1	Anaplastic Lymphoma KinaseIBA 04/2007

Therapy/Procedure

12	Therapeutics 01/2022 - 12/2003
2	Hematopoietic Stem Cell Transplantation 01/2021 - 05/2005
2	Aftercare (After-Treatment) 12/2002 - 03/2002
1	Drug Therapy (Chemotherapy) 01/2020
1	Induction Chemotherapy 01/2020
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2009
1	Molecular Targeted Therapy 05/2008